Breaking News Instant updates and real-time market news.

GM

General Motors

$34.73

-0.44 (-1.25%)

, TSLA

Tesla

$344.96

6.34 (1.87%)

20:27
01/10/19
01/10
20:27
01/10/19
20:27

General Motors' Cadillac to launch electric cars, Reuters reports

General Motors' (GM) Cadillac will introduce a luxury electric car model in a bid to compete with Tesla (TSLA), Reuters reports, citing two people familiar with the company plans. The report states that GM will make an announcement on Friday as part of its investor update about its upcoming BEV3 platform, though the exact details regarding the timing and location of the model launch, as well as the production of its battery system, will not be disclosed. Reference Link

GM

General Motors

$34.73

-0.44 (-1.25%)

TSLA

Tesla

$344.96

6.34 (1.87%)

  • 11

    Jan

  • 15

    Jan

  • 15

    Jan

  • 06

    Feb

GM General Motors
$34.73

-0.44 (-1.25%)

01/07/19
01/07/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. General Motors (GM) upgraded to Outperform from Market Perform at BMO Capital with analyst Richard Carlson citing a "brighter spotlight" being placed on the GM Cruise model in 2019 leading to more appropriate value being priced into the shares. 2. Alphabet (GOOG, GOOGL), Adobe (ADBE), and Salesforce (CRM) were upgraded to Buy from Hold at Pivotal Research. 3. Citi (C) upgraded to Outperform from Neutral at Macquarie with analyst David Konrad saying despite macro uncertainties, he sees Citi's stock as compelling due to his expectations for improving performance, continued operating leverage and credit risk concerns that he views as overdone. 4. Micron (MU) upgraded to Outperform from Market Perform at BMO Capital with analyst Ambrish Srivastava citing valuation. 5. Dillard's (DDS) upgraded to Neutral from Underweight at JPMorgan with analyst Matthew Boss saying he sees a more balanced risk/reward with the stock underperforming the over the past few years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/07/19
BMOC
01/07/19
UPGRADE
Target $41
BMOC
Outperform
General Motors upgraded to Outperform at BMO Capital on Cruise potential
As reported earlier, BMO Capital analyst Richard Carlson upgraded General Motors to Outperform from Market Perform and also raised his price target to $41 from $38. The analyst cites a "brighter spotlight" being placed on the GM Cruise model in 2019 leading to more appropriate value being priced into the shares. Carlson also believes that General Motors' restructuring measures will yield improved profitability and higher free cash flows while also generating "cyclical resilience" for the stock that should generate a higher multiple.
01/07/19
BMOC
01/07/19
UPGRADE
BMOC
Outperform
General Motors upgraded to Outperform from Market Perform at BMO Capital
12/14/18
12/14/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Outperform at Wedbush and a Hold at Deutsche Bank. 2. New York Times (NYT) initiated with an Outperform at Evercore ISI. 3. Ford (F) and General Motors (GM) were initiated with a Buy at Deutsche Bank, while Autoliv (ALV) was initiated with a Sell. 4. AstraZeneca (AZN) initiated with a Buy at SunTrust while GlaxoSmithKline (GSK) was initiated with a Hold. 5. DaVita (DVA) initiated with an Overweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
TSLA Tesla
$344.96

6.34 (1.87%)

01/10/19
MSCO
01/10/19
NO CHANGE
Target $291
MSCO
Equal Weight
Morgan Stanley 'unconvinced' on Tesla long-term future in China after Musk trip
Morgan Stanley analyst Adam Jonas said it is notable that Elon Musk, "one of the most well-known U.S. CEOs," physically traveled to China and he thinks Tesla may have some negotiating power to secure more favorable, or at least "less unfavorable," trading parameters for the import and sale of its electric vehicles in China while the Shanghai Gigafactory is being ramped up. Tesla's success in securing improved trade terms with China could be worth "many tens of thousands" in Model 3 volume over the next 12 months and significantly impact its ability to make or beat consensus forecasts, said Jonas, who noted that he remains "unconvinced of Tesla's long-term future in China." Jonas keeps an Equal Weight rating and $291 price target on Tesla shares.
01/03/19
DBAB
01/03/19
NO CHANGE
Target $375
DBAB
Hold
Tesla selloff yesterday on price cuts is justified, says Deutsche Bank
Yesterday's negative stock reaction to Tesla's U.S. price cuts is justified, as the move should put pressure on consensus 2019 earnings and free cash flow estimates, and raises "real questions" about the elasticity of demand for the company's vehicles, Deutsche Bank analyst Emmanuel Rosner tells investors in a research note. The analyst, however, believes Tesla's near-term news flow could be more supportive, as he expects "robust" Q4 earnings and does not see the need for a capital raise. Further, he points out that the current stock price leaves some larger upside potential to his $375 price target. Rosner, nonetheless, keeps a Hold rating on Tesla shares.
01/03/19
JPMS
01/03/19
NO CHANGE
Target $220
JPMS
Underweight
JPMorgan cuts Tesla target to $220, keeps Underweight rating on shares
JPMorgan analyst Ryan Brinkman lowered his price target for Tesla to $220 from $225 after the company announced yesterday that Q4 deliveries tracked 90,700 vehicles, softer than his firm's estimate of 93,000. Most closely watched Model 3 deliveries totaled 63,150 in Q4 versus the consensus of 63,698 and JPMorgan's estimate of 65,000, Brinkman tells investors in a research note. Further, the announced vehicle price cuts suggest soft underlying demand, adds the analyst. He cut his Q4 earnings per share estimate for Tesla to 77c from 93c and 2019 estimate to $3.35 from $3.95. With "material downside" to his December 2019 price target of $220, Brinkman keeps an Underweight rating on Tesla.
01/02/19
GSCO
01/02/19
NO CHANGE
Target $225
GSCO
Sell
Tesla production below expectations, demand in question, says Goldman Sachs
Goldman Sachs analyst David Tamberrino said Tesla's Q4 delivery numbers "came in okay," but the company's production came in worse than he expected. He also believes demand is in question following the company's price cut and thinks the implied increase in inventory levels for the Model 3 is a concern. The question of demand, as well as the lack of re-affirmation of positive net income and FCF guidance, contributed to the shares' underperformance today, Tamberrino tells investors. He keeps a Sell rating on Tesla shares with a $225 price target.

TODAY'S FREE FLY STORIES

TGP

Teekay LNG

$12.80

0.23 (1.83%)

07:33
01/22/19
01/22
07:33
01/22/19
07:33
Upgrade
Teekay LNG rating change  »

Teekay LNG upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CABO

Cable One

$850.40

8.96 (1.06%)

07:32
01/22/19
01/22
07:32
01/22/19
07:32
Upgrade
Cable One rating change  »

Cable One upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRDCY

Bridgestone

$0.00

(0.00%)

07:32
01/22/19
01/22
07:32
01/22/19
07:32
Downgrade
Bridgestone rating change  »

Bridgestone downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVCN

Neovasc

$0.75

0.0001 (0.01%)

, EW

Edwards Lifesciences

$168.41

9.29 (5.84%)

07:31
01/22/19
01/22
07:31
01/22/19
07:31
Hot Stocks
Neovasc announces dismissal of claim brought by Edwards Lifesciences »

Neovasc (NVCN) announced…

NVCN

Neovasc

$0.75

0.0001 (0.01%)

EW

Edwards Lifesciences

$168.41

9.29 (5.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

  • 31

    Jan

STT

State Street

07:30
01/22/19
01/22
07:30
01/22/19
07:30
Downgrade
State Street rating change  »

State Street downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WERN

Werner

, KNX

Knight-Swift

$32.69

1.005 (3.17%)

07:30
01/22/19
01/22
07:30
01/22/19
07:30
Recommendations
Werner, Knight-Swift analyst commentary  »

Deutsche Bank names…

WERN

Werner

KNX

Knight-Swift

$32.69

1.005 (3.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Apr

PANW

Palo Alto Networks

$203.29

0.06 (0.03%)

, FTNT

Fortinet

$70.50

-2.1 (-2.89%)

07:30
01/22/19
01/22
07:30
01/22/19
07:30
Upgrade
Palo Alto Networks, Fortinet rating change  »

Palo Alto Networks…

PANW

Palo Alto Networks

$203.29

0.06 (0.03%)

FTNT

Fortinet

$70.50

-2.1 (-2.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 06

    Feb

  • 25

    Feb

AIG

AIG

$44.15

0.86 (1.99%)

07:27
01/22/19
01/22
07:27
01/22/19
07:27
Recommendations
AIG analyst commentary  »

Deutsche Bank closes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMMU

Immunomedics

$13.31

-4.75 (-26.30%)

07:25
01/22/19
01/22
07:25
01/22/19
07:25
Downgrade
Immunomedics rating change  »

Immunomedics downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPRO

GoPro

$4.92

0.015 (0.31%)

07:25
01/22/19
01/22
07:25
01/22/19
07:25
Recommendations
GoPro analyst commentary  »

GoPro still…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 25

    Feb

07:25
01/22/19
01/22
07:25
01/22/19
07:25
General news
FX Update »

FX Update: A generally…

SRNE

Sorrento Therapeutics

$2.30

0.04 (1.77%)

07:23
01/22/19
01/22
07:23
01/22/19
07:23
Hot Stocks
Sorrento Therapeutics announces interim RTX study data »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LXRX

Lexicon

$5.96

-1.73 (-22.50%)

, SNY

Sanofi

$41.50

-0.54 (-1.28%)

07:23
01/22/19
01/22
07:23
01/22/19
07:23
Recommendations
Lexicon, Sanofi analyst commentary  »

Lexicon price target…

LXRX

Lexicon

$5.96

-1.73 (-22.50%)

SNY

Sanofi

$41.50

-0.54 (-1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

FTNT

Fortinet

$70.50

-2.1 (-2.89%)

07:22
01/22/19
01/22
07:22
01/22/19
07:22
Downgrade
Fortinet rating change  »

Fortinet downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 06

    Feb

  • 25

    Feb

ATI

Allegheny Technologies

$25.48

0.5 (2.00%)

07:22
01/22/19
01/22
07:22
01/22/19
07:22
Earnings
Allegheny Technologies reports Q4 EPS 30c, consensus 34c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

IRMD

iRadimed

$25.77

0.32 (1.26%)

07:21
01/22/19
01/22
07:21
01/22/19
07:21
Hot Stocks
iRadimed suspends sales of 3880 patient vital signs monitoring system »

iRadimed announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AINV

Apollo Investment

$14.51

-0.01 (-0.07%)

07:19
01/22/19
01/22
07:19
01/22/19
07:19
Upgrade
Apollo Investment rating change  »

Citi upgrades Apollo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

FITB

Fifth Third

$27.00

0.59 (2.23%)

, MBFI

MB Financial

$44.59

0.83 (1.90%)

07:19
01/22/19
01/22
07:19
01/22/19
07:19
Hot Stocks
Fifth Third sees FY19 NII up approx. 3% from FY18 »

Sees Q1 NII down 1.5%-2%…

FITB

Fifth Third

$27.00

0.59 (2.23%)

MBFI

MB Financial

$44.59

0.83 (1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

ICE

IntercontinentalExchange

, CME

CME Group

$183.47

2.25 (1.24%)

07:18
01/22/19
01/22
07:18
01/22/19
07:18
Recommendations
IntercontinentalExchange, CME Group analyst commentary  »

Citi upgrades ICE to Buy,…

ICE

IntercontinentalExchange

CME

CME Group

$183.47

2.25 (1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

  • 08

    May

  • 28

    May

MO

Altria Group

$48.29

1.22 (2.59%)

, PM

Philip Morris

$73.77

1.25 (1.72%)

07:18
01/22/19
01/22
07:18
01/22/19
07:18
Downgrade
Altria Group, Philip Morris rating change  »

Altria Group downgraded…

MO

Altria Group

$48.29

1.22 (2.59%)

PM

Philip Morris

$73.77

1.25 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 07

    Feb

  • 18

    Feb

AUPH

Aurinia Pharmaceuticals

$7.54

0.11 (1.48%)

, AGN

Allergan

$160.28

3.74 (2.39%)

07:16
01/22/19
01/22
07:16
01/22/19
07:16
Periodicals
Aurinia CEO says VOS could become blockbuster treatment, STATNews reports »

Though Aurinia…

AUPH

Aurinia Pharmaceuticals

$7.54

0.11 (1.48%)

AGN

Allergan

$160.28

3.74 (2.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

  • 18

    May

  • 28

    May

AMZN

Amazon.com

$1,696.01

4.01 (0.24%)

07:14
01/22/19
01/22
07:14
01/22/19
07:14
Recommendations
Amazon.com analyst commentary  »

Amazon.com remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 31

    Jan

  • 20

    Feb

  • 03

    Mar

CRSP

Crispr Therapeutics

$37.21

1.22 (3.39%)

07:14
01/22/19
01/22
07:14
01/22/19
07:14
Hot Stocks
Crispr Therapeutics signs collaboration agreement with ProBioGen »

Crispr Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STZ

Constellation Brands

$164.13

3.78 (2.36%)

07:13
01/22/19
01/22
07:13
01/22/19
07:13
Initiation
Constellation Brands initiated  »

Constellation Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

HBM

Hudbay Minerals

$5.65

0.03 (0.53%)

07:12
01/22/19
01/22
07:12
01/22/19
07:12
Downgrade
Hudbay Minerals rating change  »

Hudbay Minerals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.